查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1872122

Duchenne氏肌肉失養症：全球市場佔有率和排名、總收入和需求預測（2025-2031年）

Duchenne Muscular Dystrophy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 85 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球Duchenne氏肌肉失養症市場規模估計為 20.67 億美元，預計到 2031 年將達到 44.49 億美元，在預測期（2025-2031 年）內複合年成長率為 13.1%。

Duchenne氏肌肉失養症是一種X染色體連鎖遺傳疾病，主要影響男孩。患有杜氏肌肉營養不良症的男孩最早在2至5歲時就開始出現肌肉無力的徵兆。這種疾病會逐漸削弱手臂、腿部和身體軀幹的骨骼肌（隨意肌）。由於進行性肌肉無力，杜氏肌肉營養不良症患者通常在7至13歲之間需要依靠輪椅出行。隨著病情進展，呼吸肌肉和心肌也會受到影響，呼吸衰竭和心臟衰竭是許多患者的主要死因，患者通常在20歲之前去世。

全球Duchenne氏肌肉失養症市場的主要企業包括Sarepta Therapeutics和PTC Therapeutics。北美是最大的市場，佔超過70%的市場佔有率，其次是歐洲和日本，各佔25%以上的市場佔有率。以產品分類，Exondys 51是最大的細分市場，佔超過55%的市場。按應用領域分類，醫院是最大的應用領域，其次是診所和居家醫療。

Duchenne氏肌肉失養症（DMD）市場主要受以下因素驅動：

1. 疾病負擔與流行病學數據

  • 1.1 發病率和患者族群

全球數據：DMD 是一種 X 連鎖遺傳疾病，全球發生率約為每 10 萬人 6 例。大多數患者為男性（由於 X 連鎖隱性遺傳，女性必須攜帶兩個缺陷基因才會生病）。

中國數據：中國DMD的發生率約為1/3853，全國約有6萬至7萬名患者。多數患者為兒童及青少年，發病高峰年齡為3至5歲。

地理分佈：歐洲（瑞典、挪威）、北美（美國、加拿大）和中國是盛行率最高的地區，約 30% 的臨床試驗在亞太地區（澳洲、日本等）進行。

  • 1.2 疾病的特徵和影響

症狀與預後：患者通常在2-3歲左右出現運動發育遲緩（例如，坐立和行走困難），12歲左右喪失行走能力，最終死於呼吸衰竭或心肺衰竭。平均壽命約40歲。併發症：約30%的患者會出現輕度智慧障礙，骨骼畸形（例如，脊椎側彎）和肌肉萎縮會顯著影響生活品質。

2. 治療進展及在研藥物

  • 2.1 非處方藥

皮質類固醇：皮質類固醇，如地夫可特（Emflaza）和伐洛酮，是傳統的治療方法，可透過其抗發炎特性減緩疾病進展，但它們也會引起副作用（如體重增加和生長抑制）。

外顯子跳躍療法：反義寡核苷酸（ASO）用於跳過突變外顯子，部分恢復Dystrophin的功能。已通過核准的藥物包括：

Exondis51（外顯子 51 跳躍，影響 13% 的 DMD 患者）、Byondis53（外顯子 53 跳躍，影響 8% 的患者）和 Amondis45（外顯子 45 跳躍）。

Viltepsiso（外顯子53跳躍療法，由日本製藥株式會社生產）。基因療法：Erebdis（SRP-9001）是第一個核准用於治療杜氏肌肉營養不良症（DMD）的基因療法。它透過腺相關病毒（AAV）載體遞送Dystrophin基因。預計其適應症將於2024年擴大至4歲以上患者（包括可行走和不可行走的患者）。

  • 2.2 正在研發的藥物和技術

基因療法：多家公司（包括 Sarepta Therapeutics 和 Roche）正在開發基因療法來治療潛在的遺傳缺陷。

細胞療法和基因編輯：基因編輯工具（例如 CRISPR 技術）在臨床前試驗中顯示出令人鼓舞的結果，但尚未大規模應用。

HDAC抑制劑：例如，吉比司他（Duvyzat）可抑制組蛋白去乙醯化酶，從而減緩肌肉萎縮。它於2024年獲得FDA核准，用於治療6歲及以上患者。

3. 政策支持與孤兒藥認定

  • 3.1 全球政策的差異

在美國，FDA已核准多種用於治療杜氏肌肉營養不良症（DMD）的藥物（例如Exondys 51和Erebdis），並加快了核准，但要求進行驗證性試驗以確認其療效。歐盟拒絕續簽部分藥物（例如Exondys 51）的核准，而英國藥品和保健產品監管署（MHRA）則維持了部分藥物的供應，這反映了地區政策的差異。

中國已將杜氏肌肉營養不良症 (DMD) 指定為首個罕見疾病，提供專款支持研究和開發，並促進新藥（如纈莫隆酮）的優先審查和報銷。

  • 3.2 孤兒藥激勵措施

稅收優惠和快速核准：許多國家透過指客製化度（例如美國的孤兒藥法案）提供稅收優惠、研發補貼和快速核准，幫助公司降低研發風險。

安全網計畫：一些國家（例如法國和德國）將對預算影響最小的藥品免於經濟分析，從而加速病患獲得藥品的速度。

4. 患者需求與組織活動

  • 4.1 患者的意願和生活品質

不斷變化的治療需求：患者及其家屬強烈希望找到能夠減少傳統荷爾蒙（包括新型分離性類固醇，如纈莫洛隆）副作用的治療方法，這推動了創新療法的研發。提高疾病認知度：患者團體（例如Duchenne氏肌肉失養症協會）正透過宣傳活動提高大眾對杜氏肌肉營養不良症的認知度，並呼籲提供更多治療選擇和醫療保險覆蓋。

  • 4.2 最佳化臨床管理

透過多學科協作進行全面管理：例如，北京兒童醫院組建了一支神經科、復健科和心臟科等部門組成的DMD專家團隊，提供終身個人化治療。

早期診斷與介入：我們利用運動功能評估、肌肉酶譜分析（肌酸激酶水平升高 20-200 倍）和基因檢測來確保早期診斷和最佳化治療。

5. 資本投資與研發趨勢

  • 5.1 製藥公司的策略

大型國際公司：Sarepta Therapeutics（外顯子跳躍療法的領導者）、羅氏（基因療法合作）和Italfarmaco（HDAC抑制劑）等公司正在推動創新治療方法的開發。

中國企業：曙方藥業（已在國內推出纈莫洛酮）、新芽基因和金維科正在投資基因治療，並透過合作收購和獨立研發將新藥推向市場。 5.2創業投資及併購

資本趨勢：從 2023 年到 2024 年，多家國際製藥公司與中國 DMD 研發公司合作（例如，Cranberry Pharmaceuticals 推出學名藥學名藥），以促進基因療法等創新治療方法的開發。

市場預測：預計從 2024 年到 2030 年，中國 DMD 藥物市場將繼續成長，創新治療方法（例如基因療法）有望主導市場並推動市場滲透率的提高。

6. 技術進步與未來方向

  • 6.1 基因治療的進展

Elevidis 的突破性進展：作為首個針對杜氏肌肉營養不良症 (DMD) 的基因療法，Elevidis 透過一次治療即可解決其根本的遺傳病因。儘管存在免疫反應和禁忌症方面的挑戰，但它代表了未來的發展方向。

檢驗長期療效：驗證性試驗（例如 EMBARK）將繼續追蹤患者的功能改善情況（例如 North Star 步態評估、站立時間），以檢驗基因療法的持久性。

  • 6.2 個人化治療與數位化

精準醫療：基於患者基因突變類型製定個人化治療方案（例如外顯子跳躍療法）將提高治療效果。數位化醫療應用：線上諮詢和遠端監測等技術（例如北京兒童醫院的「綠色通道」系統）將最佳化病患管理，改善就醫體驗。

Duchenne氏肌肉失養症(DMD) 市場成長的主要促進因素包括疾病負擔、治療進展（尤其是基因療法）、政策支持、患者需求不斷成長以及資本投資。展望未來，更多創新治療方法的核准和醫保覆蓋範圍的擴大預計將進一步刺激市場需求，推動基因療法等前沿技術成為主流治療方法。

本報告旨在按地區/國家、類型和應用對全球Duchenne氏肌肉失養症市場進行全面分析，重點關注總收入、市場佔有率和主要企業的排名。

本報告以收益為準，以2024年為基準年，對Duchenne氏肌肉失養症市場規模、估計值和預測進行了分析，並涵蓋了2020年至2031年的歷史數據和預測數據。定量和定性分析將幫助讀者制定Duchenne氏肌肉失養症業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

按類型分類的細分市場

  • 埃克森美孚51號
  • 恩弗拉扎
  • 特蘭斯拉納

應用領域

  • 醫院
  • 診所
  • 居家醫療

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Duchenne Muscular Dystrophy was estimated to be worth US$ 2067 million in 2024 and is forecast to a readjusted size of US$ 4449 million by 2031 with a CAGR of 13.1% during the forecast period 2025-2031.

Duchenne Muscular Dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc. North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent. In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

The Duchenne muscular dystrophy (DMD) market is primarily driven by the following factors:

1. Disease Burden and Epidemiological Data

  • 1.1 Incidence and Patient Population

Global Data: DMD is a rare, X-linked genetic disease with a global incidence of approximately 6 cases per 100,000 people, with the majority of patients being male (due to recessive inheritance of the X chromosome, females require two defective copies to develop the disease).

China Data: The incidence of DMD in China is approximately 1 in 3,853, with approximately 60,000 to 70,000 patients nationwide. The majority of patients are children and adolescents, with the peak incidence occurring between the ages of 3 and 5 years.

Regional Distribution: Europe (Sweden and Norway), North America (the United States and Canada), and China are the most prevalent regions, with the Asia-Pacific region (such as Australia and Japan) contributing approximately 30% of clinical trials.

  • 1.2 Disease Characteristics and Impact

Symptoms and Prognosis: Patients typically experience delayed motor development (e.g., difficulty sitting and walking) at 2-3 years of age, lose the ability to walk around 12 years of age, and ultimately die from respiratory or cardiopulmonary failure. The average life expectancy is approximately 40 years. Complications: Approximately 30% of patients experience mild intellectual disability, and skeletal deformities (such as scoliosis) and muscle atrophy significantly impact their quality of life.

2. Treatment Advances and Drugs in Development

  • 2.1 Marketed Drugs

Corticosteroids: Corticosteroids such as deflazacort (Emflaza) and vamorolone are traditional treatments that slow disease progression through their anti-inflammatory effects, but they can also cause side effects (such as weight gain and growth suppression).

Exon-skipping therapy: Antisense oligonucleotides (ASOs) are used to skip the mutated exon, restoring some dystrophin function. Approved drugs include:

Exondys 51 (exon 51 skipping, affecting 13% of DMD patients), Vyondys 53 (exon 53 skipping, affecting 8%), and Amondys 45 (exon 45 skipping).

Viltepsiso (exon 53 skipping, manufactured by Nippon Shinyaku Co., Ltd.). Gene Therapy: Elevidys (SRP-9001) is the first approved gene therapy for DMD. It delivers the dystrophin gene via an AAV vector. Its indication will be expanded to patients aged 4 years and older (regardless of ambulatory status) in 2024.

  • 2.2 Drugs and Technologies in Development

Gene Therapy: Several companies (such as Sarepta Therapeutics and Roche) are advancing gene therapies to address the underlying genetic defect.

Cell Therapy and Gene Editing: Gene editing tools such as CRISPR technology have shown promise in preclinical studies but have yet to enter large-scale application.

HDAC inhibitors: For example, givinostat (Duvyzat) inhibits histone deacetylases to slow muscle degeneration and was approved by the FDA in 2024 for patients aged 6 years and older.

3. Policy Support and Orphan Drug Designation

  • 3.1 Global Policy Differences

US: The FDA has approved several DMD drugs (such as Exondys 51 and Elevidys) through accelerated approval, but requires confirmatory trials to verify efficacy. The European Union (EU) has refused to renew approval for some drugs (such as Exondys 51), while the UK's MHRA has retained access to some drugs, reflecting regional policy differences.

China has included DMD in its first list of rare diseases, providing dedicated funding to support research and development, and promoting priority review and reimbursement of new drugs (such as valmorolone).

  • 3.2 Orphan Drug Incentives

Tax Incentives and Expedited Approval: Most countries use orphan drug designation (such as the US Orphan Drug Act) to provide tax breaks, research and development subsidies, and fast-track approvals, reducing R&D risks for companies.

Safety Net Programs: Some countries (such as France and Germany) waive economic analysis for drugs with minimal budgetary impact, accelerating patient access.

4. Patient Needs and Organizational Activities

  • 4.1 Patient Demands and Quality of Life

Evolving Treatment Needs: Patients and families have a strong demand for treatments that reduce the side effects of traditional hormones (such as newer dissociative steroids like valmorolone), driving the development of innovative therapies. Raising Disease Awareness: Patient organizations (such as the Duchenne Muscular Dystrophy Association) are raising public awareness of DMD through advocacy, advocating for more treatment options and medical insurance coverage.

  • 4.2 Optimizing Clinical Management

Multidisciplinary Integrated Management: For example, Beijing Children's Hospital has established a multidisciplinary DMD team (including neurology, rehabilitation, and cardiology) to provide personalized treatment throughout the lifespan.

Early Diagnosis and Intervention: Motor function assessments, muscle enzyme profiles (creatine kinase elevation of 20-200 times), and genetic testing are used to achieve early diagnosis and optimize the therapeutic window.

5. Capital Investment and R&D Trends

  • 5.1 Pharmaceutical Company Strategies

International giants: Sarepta Therapeutics (leading in exon skipping therapies), Roche (gene therapy collaborations), Italfarmaco (HDAC inhibitors), and other companies are driving the development of innovative therapies.

Chinese companies: Shufang Pharmaceuticals (valmorolone launched domestically), New Sprout Gene, and Jinweike are investing in gene therapy, bringing new drugs to market through collaborative acquisitions or independent R&D. 5.2 Venture Capital and M&A

Capital Activity: In 2023-2024, several international pharmaceutical companies entered into collaborations with Chinese DMD R&D companies (e.g., Cranbury Pharmaceuticals introduced generic versions of deflazacort), promoting the development of innovative therapies such as gene therapy.

Market Forecast: China's DMD drug market is expected to continue to grow from 2024 to 2030, with innovative therapies (e.g., gene therapy) dominating the market and driving increased market penetration.

6. Technological Advances and Future Directions

  • 6.1 Gene Therapy Breakthroughs

Elevidys' Milestone: As the first DMD gene therapy, Elevidys addresses the underlying genetic cause with a one-time treatment. Despite challenges with immunity and contraindications, it represents a future direction.

Long-Term Efficacy Verification: Confirmatory trials (e.g., the EMBARK trial) will continuously track patient functional improvements (e.g., North Star Walk Assessment, Time to Stand), verifying the durability of gene therapy.

  • 6.2 Personalized Treatment and Digitalization

Precision Medicine: Developing personalized treatment plans based on the patient's genetic mutation type (e.g., exon skipping therapy) improves efficacy. Digital healthcare applications: Technologies such as online diagnosis and treatment, remote monitoring (such as the "Green Channel" system at Beijing Children's Hospital) optimize patient management and enhance the medical experience.

The growth of the Duchenne muscular dystrophy (DMD) market is primarily driven by the disease burden, treatment advances (particularly gene therapy), policy support, escalating patient needs, and capital investment. In the future, with the approval of more innovative therapies and expanded medical insurance coverage, market demand will be further unleashed, and cutting-edge technologies such as gene therapy are expected to become mainstream treatments.

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Duchenne Muscular Dystrophy by region & country, by Type, and by Application.

The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.

Market Segmentation

By Company

  • Sarepta Therapeutics
  • PTC Therapeutics
  • Pfizer
  • Bristol-Myers Squibb
  • Italfarmaco
  • Santhera Pharmaceuticals

Segment by Type

  • Exondys 51
  • Emflaza
  • Translarna

Segment by Application

  • Hospitals
  • Clinics
  • Home Care

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Duchenne Muscular Dystrophy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Duchenne Muscular Dystrophy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Duchenne Muscular Dystrophy in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Duchenne Muscular Dystrophy Product Introduction
  • 1.2 Global Duchenne Muscular Dystrophy Market Size Forecast (2020-2031)
  • 1.3 Duchenne Muscular Dystrophy Market Trends & Drivers
    • 1.3.1 Duchenne Muscular Dystrophy Industry Trends
    • 1.3.2 Duchenne Muscular Dystrophy Market Drivers & Opportunity
    • 1.3.3 Duchenne Muscular Dystrophy Market Challenges
    • 1.3.4 Duchenne Muscular Dystrophy Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Duchenne Muscular Dystrophy Players Revenue Ranking (2024)
  • 2.2 Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025)
  • 2.3 Key Companies Duchenne Muscular Dystrophy Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Duchenne Muscular Dystrophy Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy
  • 2.6 Duchenne Muscular Dystrophy Market Competitive Analysis
    • 2.6.1 Duchenne Muscular Dystrophy Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Duchenne Muscular Dystrophy Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Exondys 51
    • 3.1.2 Emflaza
    • 3.1.3 Translarna
  • 3.2 Global Duchenne Muscular Dystrophy Sales Value by Type
    • 3.2.1 Global Duchenne Muscular Dystrophy Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Duchenne Muscular Dystrophy Sales Value, by Type (2020-2031)
    • 3.2.3 Global Duchenne Muscular Dystrophy Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospitals
    • 4.1.2 Clinics
    • 4.1.3 Home Care
  • 4.2 Global Duchenne Muscular Dystrophy Sales Value by Application
    • 4.2.1 Global Duchenne Muscular Dystrophy Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Duchenne Muscular Dystrophy Sales Value, by Application (2020-2031)
    • 4.2.3 Global Duchenne Muscular Dystrophy Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Duchenne Muscular Dystrophy Sales Value by Region
    • 5.1.1 Global Duchenne Muscular Dystrophy Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Duchenne Muscular Dystrophy Sales Value by Region (2020-2025)
    • 5.1.3 Global Duchenne Muscular Dystrophy Sales Value by Region (2026-2031)
    • 5.1.4 Global Duchenne Muscular Dystrophy Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.2.2 North America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.3.2 Europe Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Duchenne Muscular Dystrophy Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.5.2 South America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Duchenne Muscular Dystrophy Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Duchenne Muscular Dystrophy Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.3.2 United States Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.4.2 Europe Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.5.2 China Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.6.2 Japan Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.7.2 South Korea Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Duchenne Muscular Dystrophy Sales Value, 2020-2031
    • 6.9.2 India Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Duchenne Muscular Dystrophy Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Sarepta Therapeutics
    • 7.1.1 Sarepta Therapeutics Profile
    • 7.1.2 Sarepta Therapeutics Main Business
    • 7.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Sarepta Therapeutics Recent Developments
  • 7.2 PTC Therapeutics
    • 7.2.1 PTC Therapeutics Profile
    • 7.2.2 PTC Therapeutics Main Business
    • 7.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.2.5 PTC Therapeutics Recent Developments
  • 7.3 Pfizer
    • 7.3.1 Pfizer Profile
    • 7.3.2 Pfizer Main Business
    • 7.3.3 Pfizer Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.3.4 Pfizer Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Pfizer Recent Developments
  • 7.4 Bristol-Myers Squibb
    • 7.4.1 Bristol-Myers Squibb Profile
    • 7.4.2 Bristol-Myers Squibb Main Business
    • 7.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Bristol-Myers Squibb Recent Developments
  • 7.5 Italfarmaco
    • 7.5.1 Italfarmaco Profile
    • 7.5.2 Italfarmaco Main Business
    • 7.5.3 Italfarmaco Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.5.4 Italfarmaco Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Italfarmaco Recent Developments
  • 7.6 Santhera Pharmaceuticals
    • 7.6.1 Santhera Pharmaceuticals Profile
    • 7.6.2 Santhera Pharmaceuticals Main Business
    • 7.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products, Services and Solutions
    • 7.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Santhera Pharmaceuticals Recent Developments

8 Industry Chain Analysis

  • 8.1 Duchenne Muscular Dystrophy Industrial Chain
  • 8.2 Duchenne Muscular Dystrophy Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Duchenne Muscular Dystrophy Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Duchenne Muscular Dystrophy Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Duchenne Muscular Dystrophy Market Trends
  • Table 2. Duchenne Muscular Dystrophy Market Drivers & Opportunity
  • Table 3. Duchenne Muscular Dystrophy Market Challenges
  • Table 4. Duchenne Muscular Dystrophy Market Restraints
  • Table 5. Global Duchenne Muscular Dystrophy Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Duchenne Muscular Dystrophy Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Duchenne Muscular Dystrophy Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Duchenne Muscular Dystrophy Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Duchenne Muscular Dystrophy
  • Table 10. Global Duchenne Muscular Dystrophy Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Duchenne Muscular Dystrophy Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Duchenne Muscular Dystrophy Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Duchenne Muscular Dystrophy Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Duchenne Muscular Dystrophy Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Duchenne Muscular Dystrophy Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Duchenne Muscular Dystrophy Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Duchenne Muscular Dystrophy Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Duchenne Muscular Dystrophy Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Duchenne Muscular Dystrophy Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Duchenne Muscular Dystrophy Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Duchenne Muscular Dystrophy Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Duchenne Muscular Dystrophy Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Sarepta Therapeutics Basic Information List
  • Table 32. Sarepta Therapeutics Description and Business Overview
  • Table 33. Sarepta Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Sarepta Therapeutics (2020-2025)
  • Table 35. Sarepta Therapeutics Recent Developments
  • Table 36. PTC Therapeutics Basic Information List
  • Table 37. PTC Therapeutics Description and Business Overview
  • Table 38. PTC Therapeutics Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of PTC Therapeutics (2020-2025)
  • Table 40. PTC Therapeutics Recent Developments
  • Table 41. Pfizer Basic Information List
  • Table 42. Pfizer Description and Business Overview
  • Table 43. Pfizer Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Pfizer (2020-2025)
  • Table 45. Pfizer Recent Developments
  • Table 46. Bristol-Myers Squibb Basic Information List
  • Table 47. Bristol-Myers Squibb Description and Business Overview
  • Table 48. Bristol-Myers Squibb Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Bristol-Myers Squibb (2020-2025)
  • Table 50. Bristol-Myers Squibb Recent Developments
  • Table 51. Italfarmaco Basic Information List
  • Table 52. Italfarmaco Description and Business Overview
  • Table 53. Italfarmaco Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Italfarmaco (2020-2025)
  • Table 55. Italfarmaco Recent Developments
  • Table 56. Santhera Pharmaceuticals Basic Information List
  • Table 57. Santhera Pharmaceuticals Description and Business Overview
  • Table 58. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Duchenne Muscular Dystrophy Business of Santhera Pharmaceuticals (2020-2025)
  • Table 60. Santhera Pharmaceuticals Recent Developments
  • Table 61. Key Raw Materials Lists
  • Table 62. Raw Materials Key Suppliers Lists
  • Table 63. Duchenne Muscular Dystrophy Downstream Customers
  • Table 64. Duchenne Muscular Dystrophy Distributors List
  • Table 65. Research Programs/Design for This Report
  • Table 66. Key Data Information from Secondary Sources
  • Table 67. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Duchenne Muscular Dystrophy Product Picture
  • Figure 2. Global Duchenne Muscular Dystrophy Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Duchenne Muscular Dystrophy Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Duchenne Muscular Dystrophy Report Years Considered
  • Figure 5. Global Duchenne Muscular Dystrophy Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Duchenne Muscular Dystrophy Revenue in 2024
  • Figure 7. Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Exondys 51 Picture
  • Figure 9. Emflaza Picture
  • Figure 10. Translarna Picture
  • Figure 11. Global Duchenne Muscular Dystrophy Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 12. Global Duchenne Muscular Dystrophy Sales Value Market Share by Type, 2024 & 2031
  • Figure 13. Product Picture of Hospitals
  • Figure 14. Product Picture of Clinics
  • Figure 15. Product Picture of Home Care
  • Figure 16. Global Duchenne Muscular Dystrophy Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 17. Global Duchenne Muscular Dystrophy Sales Value Market Share by Application, 2024 & 2031
  • Figure 18. North America Duchenne Muscular Dystrophy Sales Value (2020-2031) & (US$ Million)
  • Figure 19. North America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Europe Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Europe Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 22. Asia Pacific Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. Asia Pacific Duchenne Muscular Dystrophy Sales Value by Region (%), 2024 VS 2031
  • Figure 24. South America Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. South America Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Middle East & Africa Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 27. Middle East & Africa Duchenne Muscular Dystrophy Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Key Countries/Regions Duchenne Muscular Dystrophy Sales Value (%), (2020-2031)
  • Figure 29. United States Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 30. United States Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 31. United States Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 32. Europe Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. Europe Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 34. Europe Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 35. China Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 36. China Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 37. China Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 38. Japan Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. Japan Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 40. Japan Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 41. South Korea Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. South Korea Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 43. South Korea Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 44. Southeast Asia Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. Southeast Asia Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 46. Southeast Asia Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 47. India Duchenne Muscular Dystrophy Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. India Duchenne Muscular Dystrophy Sales Value by Type (%), 2024 VS 2031
  • Figure 49. India Duchenne Muscular Dystrophy Sales Value by Application (%), 2024 VS 2031
  • Figure 50. Duchenne Muscular Dystrophy Industrial Chain
  • Figure 51. Duchenne Muscular Dystrophy Manufacturing Cost Structure
  • Figure 52. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 53. Bottom-up and Top-down Approaches for This Report
  • Figure 54. Data Triangulation
  • Figure 55. Key Executives Interviewed